Our Global Business
Expanding our presence throughout the world
With a proud history of contributing to international exchange, we are active on the global stage.
Guided by a philosophy that the exchange of ideas in medical science knows no borders, we have advocated and implemented programs such as the French-Japanese Allergy Conference and the Chinese-Japanese Meeting on Immunology and Allergology . In our current business we have also focused on expanding our activities on a global scale, establishing affiliated companies and offices in a range of locations around the world.
In addition to exporting our own products, we also import high-quality pharmaceuticals and medical devices from overseas.
Leveraging our global network, we aim to serve as a link for medical care across the world.
Nippon Zoki Pharmaceutical (NZP) actively works to export the pharmaceuticals it manufactures and sells to patients and medical professionals around the world. We have made a significant contribution to pain management in China for over 20 years since obtaining approval for our analgesic drug products for use in hospitals and clinics in China in 1994.
There are also many outstanding pharmaceuticals and medical devices outside Japan, and we actively seek products with the potential to benefit patients and medical professionals in Japan. We currently import a variety of products from Europe and East Asia, and will continue striving to introduce a range of new products and technologies to Japan.
Sites in China and Vietnam
Our affiliates in China and Vietnam play a key role in ensuring the quality control and stable supply of NZP’s core pharmaceutical products. In China, we have established affiliates Xiaoxi Medical Consulting (Beijing) Co., Ltd. and Shanghai Konishi Biological Technology Co., Ltd., and in addition to manufacturing raw materials for pharmaceuticals , we also sell pharmaceutical products throughout the country. Meanwhile, our two affiliates in Vietnam, Konishi Biotechnology Vietnam Co., Ltd. and Nippon Zoki Vietnam Co. manufacture raw materials for pharmaceuticals and other products.
Partner Research Institutions Outside Japan
- National Institutes of Health (NIH) (U.S.)
- University of California, San Diego (U.S.)
- University of California, Davis (U.S.)
- The State University of New York at Stony Brook (U.S.)
- Emory University (U.S.)
- The Medical University of South Carolina (U.S.)
- Cedars-Sinai Medical Center (U.S.)
- Brigham & Women’s Hospital, Harvard Medical School (U.S.)
- Tufts University (U.S.)
- University of California, San Francisco (U.S.)
- University of Fribourg (Switzerland)
- Institute of Experimental Endocrinology, Slovak Academy of Sciences (Slovakia)
- Ghent University (Belgium)
- Newcastle University (U.K.)
- University of London (U.K.)
- P.K. Anokhin Institute of Normal Physiology, Russian Academy of Sciences (Russia)
- Shanghai Second Medical University ( China)
- The Capital University of Economics and Business (China)
- Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College (China)
- Shanghai Institute of Biological Products, Ministry of Public Health (China)
- Université catholique de Louvain (Belgium)
- Harbin Medical University (China)